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Introduction: Vandetanib is a once-daily oral agent that selectively
inhibits vascular endothelial growth factor receptor, epidermal
growth factor receptor, and RET (REarranged during Transfection)
signaling.
Methods: This Phase I study investigated the safety, tolerability,
and pharmacokinetics of vandetanib when administered with either
gemcitabine plus cisplatin (GC) or vinorelbine plus cisplatin (VC) in
patients with previously untreated locally advanced or metastatic
non-small cell lung cancer.
Results: Seventeen patients received vandetanib 100 mg/d plus VC
(n  9) or GC (n  8). Three dose-limiting toxicities were reported
in each treatment group: vandetanib  VC (pulmonary artery
thrombosis and asymptomatic QTc prolongation [n  2]); vandet-
anib  GC (peripheral ischemia [due to arterial occlusion], pulmo-
nary embolism, and limb venous thrombosis). The protocol defini-
tion of a tolerable dose was not met, and no patients were recruited
to receive vandetanib 300 mg plus VC or GC. There was no apparent
pharmacokinetic interaction between vandetanib and vinorelbine or
gemcitabine, but there was an approximate 30% increase in the
exposure to cisplatin, which may be due to accumulation of total
platinum and/or an interaction with vandetanib.
Conclusions: In this study, in patients with previously untreated
advanced non-small cell lung cancer, vandetanib 100 mg/d in
combination with either VC or GC was not tolerated.
Key Words: NSCLC, Vandetanib, Combination, Chemotherapy,
Pharmacokinetics.
(J Thorac Oncol. 2010;5: 1285–1288)
Vandetanib is a once-daily oral inhibitor of vascular endo-thelial growth factor receptor- and epidermal growth
factor receptor-dependent signaling,1 both of which are key
pathways in non-small cell lung cancer (NSCLC). Vandet-
anib also inhibits RET (REarranged during Transfection)
kinase activity, an important growth driver in certain types of
thyroid cancer.2 Phase III evaluation of vandetanib has dem-
onstrated evidence of antitumor activity in patients with
previously treated advanced NSCLC both as a monotherapy3
and in combination with pemetrexed4 or docetaxel.5
Both gemcitabine plus cisplatin (GC) and vinorelbine plus
cisplatin (VC) are indicated for first-line treatment of patients
with advanced NSCLC. The addition of anti-vascular endothe-
lial growth factor therapy to platinum-based doublet chemother-
apy has demonstrated a survival advantage in previously un-
treated patients with advanced NSCLC.6 Because vandetanib
targets vascular endothelial growth factor-dependent tumor an-
giogenesis, this background provided a reasonable rationale for
preliminary evaluation of vandetanib in combination with GC or
VC in the first-line setting. The primary objective of this phase
I, multicenter, open-label study (6474IL0054) was to evaluate
the safety, tolerability, and pharmacokinetics of vandetanib with
GC or VC in patients with previously untreated advanced or
metastatic NSCLC.
PATIENTS AND METHODS
Eligibility criteria included stage IIIB to IV NSCLC
suitable for first-line therapy with GC or VC; World Health
Organization performance status of 0 or 1; life expectancy
12 weeks; acceptable cardiac, hematopoietic, hepatic, and
renal function; no prior chemotherapy or other systemic
anticancer therapy; and no radiotherapy or major surgery
within the 4 weeks preceding the start of study therapy.
Patients with squamous histology were eligible, as were
patients with pretreated clinically stable brain metastases.
In the first cohort, up to 10 patients in each treatment
group were to receive continuous once-daily oral doses of
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vandetanib 100 mg with up to six standard 21-day treatment
cycles of GC (G: 1250 mg/m2 intravenous [IV], days 1 and 8;
C: 75 mg/m2 IV, day 1) or VC (V: 25 mg/m2 IV, days 1 and
8; C: 75 mg/m2 IV, day 1). The decision to recruit patients
into the GC or VC treatment groups was based on investiga-
tor preference and local prescribing policy. Following safety
review of at least six evaluable patients, if a dose-limiting
toxicity (DLT) that was considered to be possibly related to
vandetanib was seen in more than two patients, enrollment
into that cohort and dose escalation was halted. If less than
two evaluable patients in the vandetanib 100 mg cohort
experienced a vandetanib-related DLT, it was planned to
enroll a second cohort of up to 10 patients in each treatment
group to receive vandetanib 300 mg in combination with GC
or VC. A patient was considered evaluable if they completed
6 weeks of treatment with vandetanib and chemotherapy or
if a DLT was experienced within the first 6 weeks of treat-
ment. There was no intrapatient dose escalation.
Adverse events (AEs) were graded according to National
Cancer Institute Common Terminology Criteria for Adverse
Events version 3. A DLT was defined as any of the following (if
considered to be possibly related to vandetanib or the combina-
tion of chemotherapy and vandetanib): grade 4 neutropenia or
thrombocytopenia lasting more than 7 days; febrile neutropenia
(temperature 38.5°C on at least two occasions in 24 hours, in
association with grade 3 or 4 neutropenia); any other drug-
related grade 3 or 4 nonhematological toxicity; QTc prolonga-
tion (a single QTc measurement 550 milliseconds; two con-
secutive QTc measurements 500 but 550 milliseconds; an
increase of 100 milliseconds from baseline; or an increase of
60 milliseconds but 100 milliseconds from baseline QTc to
a QTc value 480 milliseconds).
For PK assessments, blood samples were collected on
the following days: vandetanib: days 2, 8, and 15 (cycle 1),
days 1, 8, 15, and 21 (cycle 2), and days 1 and 2 (cycle 3);
gemcitabine: day 1 (multiple samples up to 1.5 hours postin-
fusion) and day 2 of cycles 1 and 3; vinorelbine: day 1
(multiple samples up to 8 hours postinfusion) and day 2 of
cycles 1 and 3; cisplatin: day 1 (multiple samples up to 8
hours postinfusion) and day 2 of cycles 1 and 3. Because
vandetanib dosing did not commence until day 2, day 1
samples enabled collection of PK data from patients treated
with chemotherapy alone. Samples taken on day 21 of cycle
2 allowed the determination of steady-state exposure to van-
detanib alone. Sampling of gemcitabine, vinorelbine, cispla-
tin, and vandetanib at the start of cycle 3 allowed the PK data
for each to be determined when administered in combination.
Plasma concentrations of vandetanib, gemcitabine (and
its active metabolite difluorodeoxyuridine [dFdU]), and vi-
norelbine were analyzed by high-performance liquid chroma-
tography with tandem mass spectrometry. Plasma concentra-
tions of platinum (measured as equivalents of cisplatin) were
determined using inductively coupled plasma-atomic emis-
sion spectrometry. All plasma concentration-time data were
analyzed using noncompartmental methods. Tumor response,
measured at baseline and approximately every 6 weeks there-
after, was assessed according to RECIST (Response Evalua-
tion Criteria In Solid Tumors, version 1.0).
RESULTS
Patients
Seventeen patients received vandetanib 100 mg  GC
(n  8) or vandetanib 100 mg  VC (n  9) (Table 1). The
first patient entered the study on July 28, 2006, and the last
patient visit was May 16, 2007. The demographic character-
istics in this study were representative of a first-line, ad-
vanced NSCLC patient population; there were more females
than males in the VC group, but this was not anticipated to
affect the safety and tolerability results of the study.
Exposure
The mean duration of vandetanib treatment was 71 days
(vandetanib  GC) and 95 days (vandetanib  VC). Three
patients in the vandetanib  GC group and four patients in
the vandetanib  VC group received more than or equal to
four cycles of combined chemotherapy. Four patients discon-
tinued all treatment during the first chemotherapy cycle:
vandetanib  GC, peripheral ischemia due to arterial occlu-
sion (n  1); vandetanib  VC, pneumonia (n  1), and a
cisplatin-related AE (tinnitus, n  1; nephrotoxicity, n  1).
Two patients in each treatment group experienced a vandet-
anib dose reduction/interruption: vandetanib  GC:pulmo-
nary embolism (n  1), interruption due to erythromycin
treatment for an AE (n 1); vandetanib VC:asymptomatic
QTc prolongation (n  2). No patients were ongoing on
vandetanib or chemotherapy at the end of the study.
Safety and Tolerability
The protocol definition of a tolerable dose was not
achieved in vandetanib 100 mg  GC or VC groups. There-
fore, no additional cohorts received vandetanib 300 mg with
GC or VC. Six patients (three on GC and three on VC)
experienced DLTs. In the vandetanib 100 mg  GC arm, one
patient each experienced pulmonary embolism (asymptom-
atic; grade 4), limb venous thrombosis (grade 3), and periph-
eral ischemia (due to arterial occlusion; grade 2). In the
TABLE 1. Patient Characteristics
Vandetanib
100 mg  GC
(n  8)
Vandetanib
100 mg  VC
(n  9)
Mean age, yr (range) 61 (40–72) 58 (46–65)
Male (n) 4 2
Female (n) 4 7
WHO performance status (n)
0 (normal activity) 1 4
1 (restricted activity) 7 5
Stage of disease (n)
IIIB 2 1
IV 6 8




GC, gemcitabine plus cisplatin; VC, vinorelbine plus cisplatin; WHO, World
Health Organization.
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vandetanib 100 mg  VC arm, one patient experienced a
DLT of pulmonary artery thrombosis (grade 2), and two
patients had asymptomatic QTc prolongation (grade 1 and
grade 4, respectively). All DLTs were reported as serious
AEs and resulted in permanent discontinuation of vandetanib
except for the patient with reported grade 4 QTc prolonga-
tion, which was not reported as serious, resolved within 2
days, and was not accompanied by any other cardiac symp-
toms or electrocardiography findings.
The AEs observed in this study were generally consis-
tent with the known safety profiles of vandetanib, GC, and
VC. Commonly occurring AEs included constipation, nausea,
and neutropenia (Table 2). Overall, nine patients had a grade
3 or 4 neutropenic AE: vandetanib  GC: neutropenia (grade
3, n  4); vandetanib  VC: neutropenia (grade 3, n  2),
neutropenia and neutropenic sepsis (both grade 4, n  1),
neutropenic sepsis and febrile neutropenia (all grade 3, n 
2), and febrile neutropenia (grade 3, n  1). Lower respira-
tory tract infection (grade 3, n  2) was the only other grade
3 or 4 AE reported in more than one patient.
Pharmacokinetics
There was no apparent effect on the steady-state expo-
sure to vandetanib 100 mg in the presence of either chemo-
therapy regimen (Table 3). Similarly, when steady-state ex-
posure to vandetanib 100 mg had been attained, this had no
apparent effect on the exposure to coadministered gemcitab-
ine (and its metabolite, dFdU) or vinorelbine (Table 4). There
was an approximately 30% increase in exposure to cisplatin
in the presence of vandetanib (Table 4).
Efficacy
Eleven patients were evaluable for preliminary efficacy
assessment (Table 5). One confirmed partial response was
TABLE 2. Adverse Events, Irrespective of Causality,




100 mg  GC
(n  8)
Vandetanib










Constipation 3 — 6 —
Nausea 5 — 4 —
Neutropenia 5 4 (G3) 4 2 (G3), 2 (G4)
Insomnia 2 — 5 1 (G3)
Anemia — — 6 1 (G3)
Dyspepsia 1 5 —
Fatigue 4 1 (G3) 2 —
Diarrhea 3 — 3 1 (G3)
Vomiting 3 — 3 —
Lethargy — — 4 —
Headache 3 1 (G3) 1 —
Lower respiratory tract
infection
1 — 3 2 (G3)
Febrile neutropenia — — 3 3 (G3)
Urinary tract infection 2 — 1 1 (G3)
Dysgeusia 2 — 1 —
Dehydration — — 3 1 (G3)
Dyspnea — — 3 1 (G3)
Groin pain — — 3 —
Hypokalemia — — 3 1 (G3)
Rash 2 — 1 —
Dizziness 2 1 (G3) — —
Peripheral ischemia 2 — — —
GC, gemcitabine plus cisplatin; VC, vinorelbine plus cisplatin.
TABLE 3. Vandetanib Pharmacokinetic Data Alone and in
Combination With Chemotherapy
Vandetanib
100 mg  GC
Vandetanib









n 4 4 3 3
AUCss
(ng  h/ml)*
9990 (23.2) 9144 (17.1) 8341 (12.0) 8386 (9.0)
Css,max
(ng/ml)*
418 (20.0) 451 (16.0) 440 (35.0) 378 (8.4)
tmax (h)† 8.0 (0,8.0) 9.0 (6.0,9.0) 7.0 (4.0,7.0) 8.0 (0,8.0)
*Values represent the geometric mean and coefficient of variation (CV%) in
parentheses.
†Values represent the median value and the range in parentheses.
AUCss, area under plasma concentration-time curve during any dosing interval at
steady state; Css,max, maximum steady-state drug concentration in plasma during dosing
interval; GC, gemcitabine plus cisplatin; tmax, time to reach maximum concentration
after drug administration; VC, vinorelbine plus cisplatin.
TABLE 4. Chemotherapy Pharmacokinetic Data Alone and










GC 4 10450 (20.0) NA 17830 (13.8)
GC  vandetanib
100 mg
4 9847 (19.2) NA 18850 (24.9)
dFdU (gemcitabine
metabolite)
GC 4 38260 (20.5) NA 38850 (14.5)
GC  vandetanib
100 mg
4 39280 (20.1) NA 36530 (19.3)
Vinorelbine
VC 3 NA 269.6 (49.1) 165.0 (92.2)
VC  vandetanib
100 mg
3 NA 229.6 (47.3) 135.7 (43.7)
Cisplatin†
VC or GC 5 NA 44650 (61.5) 3519 (13.8)
VC or GC 
vandetanib 100 mg
5 NA 59240 (65.6) 5027 (18.1)
*Values represent the geometric mean and coefficient of variation (CV%) in
parentheses.
†Only 2 patients were assessable for cisplatin PK in the vandetanib  GC group.
The cisplatin data for both treatment groups were therefore combined.
AUC, area under the plasma concentration-time curve from zero to infinity;
AUC(0-t), area under the plasma concentration-time curve from zero to the time of the
last quantifiable concentration; Cmax, maximum plasma drug concentration after single
dose administration; dFdU, difluorodeoxyuridine; GC, gemcitabine plus cisplatin; VC,
vinorelbine plus cisplatin.
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observed (vandetanib 100 mg  GC). After two cycles of
vandetanib  GC, a routine CT scan in this patient showed
stable disease and pulmonary emboli. Vandetanib treatment
was stopped, and the partial response was observed after
continued GC treatment.
DISCUSSION
In this study, vandetanib 100 mg in combination with
GC or VC was not tolerated as a first-line treatment for
NSCLC. The DLTs observed in this study were predomi-
nantly thromboembolic events. Such events are commonly
observed in patients with advanced cancer, and the underly-
ing disease may have been a contributing factor. However, a
causal relationship to cisplatin and/or vandetanib could not be
excluded. Cisplatin is known to trigger platelet aggregation
and/or enhance thromboxane formation by platelets,7 and it is
possible to hypothesize that an interaction with vandetanib on
coagulation may have occurred. However, in vitro, vandet-
anib alone did not increase the coagulation index (ratio of
endothelial cell surface tissue factor activity to tissue factor
pathway inhibitor activity) and significantly inhibited the
increased coagulation index resulting from treatment of en-
dothelial cells with cisplatin and gemcitabine combined.8 It is
worth noting that patients receiving vandetanib 100 mg/d in
combination with pemetrexed9 or docetaxel10 did not show an
increase in thrombotic events during phase III evaluation of
vandetanib in pretreated advanced NSCLC.
Based on the limited number of patients (n  3–5)
evaluable for PK, there did not appear to be any PK interac-
tion between vandetanib and gemcitabine or vinorelbine
when given in combination. The increase in exposure to
cisplatin may be due to accumulation of total platinum in
plasma, as has been observed previously with cisplatin mono-
therapy.11 Another possibility is a potential interaction be-
tween cisplatin and vandetanib. Vandetanib has been shown
to inhibit the organic cation transporter 2 (AstraZeneca study
KMX083; data on file), which mediates cisplatin uptake in renal
proximal tubules and is involved in cisplatin nephrotoxicity.12
Inhibition of the organic cation transporter 2 by vandetanib may
result in reduced proximal tubule uptake and, therefore, in-
creased plasma levels of cisplatin. However, vandetanib did not
seem to increase cisplatin-induced nephrotoxicity in this study
(there was one AE of nephrotoxicity [Common Terminology
Criteria for Adverse Events grade 1; vandetanib  GC arm]).
The use of vandetanib with cisplatin has also been
investigated in patients with untreated, advanced head and
neck cancer. In an ongoing phase I study, vandetanib 100
mg/d appears to be tolerable in combination with weekly
cisplatin 30 mg/m2 and radiotherapy.13 An earlier phase II
study in first-line NSCLC showed that vandetanib could be
safely administered with paclitaxel and carboplatin.14 Based
on the results of this study, combining vandetanib with
cisplatin plus gemcitabine or vinorelbine is not a feasible
first-line regimen for NSCLC.
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TABLE 5. Tumor Assessment
Best Overall
Response (RECIST)
Vandetanib 100 mg 
GC (n  8)
Vandetanib 100 mg 
VC (n  9)
Partial response 1 0
Stable disease 8 wk 3 1
Progressive disease 1 5
Not evaluable 3 3
GC, gemcitabine plus cisplatin; RECIST, Response Evaluation Criteria In Solid
Tumors; VC, vinorelbine plus cisplatin.
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